Literature DB >> 21303668

Central substance P NK₁ receptors are involved in fever induced by LPS but not by IL-1β and CCL3/MIP-1α in rats.

R C Reis1, H O Brito, D Fraga, D A Cabrini, A R Zampronio.   

Abstract

Substance P (SP) is a neuropeptide that can modulate inflammatory mediator release through activation of NK(1) receptors (NK(1)R). Some studies have also suggested the involvement of SP in lipopolysaccharide (LPS)-induced fever. However, the precise contribution of this neuropeptide to the pathways activated during fever is unknown. In this study we investigated the effect of a selective NK(1)R antagonist, SR140333B, on the febrile response induced by LPS and cytokines. Our results show that the systemic injection of SR140333B did not modify the fever induced by LPS at a dose that is able to reduce protein extravasation induced by SP in the skin. On the other hand, intracerebroventricular administration of SR140333B significantly reduced the fever induced by peripheral injection of LPS. These data emphasize an important role for SP in the central nervous system during the febrile response to LPS, and are reinforced by the fact that intracerebroventricular injection of SP also induced fever in a dose-dependent manner in captopril-treated rats. Considering that the febrile response can result from the generation of several endogenous pyrogens, among them interleukin (IL)-1β and macrophage inflammatory protein-1α (CCL3/MIP-1α), we also examined the effect of SR140333B on the fever induced by these cytokines which act through prostaglandin-dependent and -independent mechanisms, respectively. Surprisingly, SR140333B did not modify the febrile response to IL-1β or CCL3/MIP-1α. Altogether these data suggest that the central action of SP is essential for LPS-, but not for IL-1β- or CCL3/MIP-1α-induced fever.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21303668     DOI: 10.1016/j.brainres.2011.02.001

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  6 in total

Review 1.  Neuropeptide receptors as potential drug targets in the treatment of inflammatory conditions.

Authors:  Erika Pintér; Gábor Pozsgai; Zsófia Hajna; Zsuzsanna Helyes; János Szolcsányi
Journal:  Br J Clin Pharmacol       Date:  2014-01       Impact factor: 4.335

2.  Fever Induced by Zymosan A and Polyinosinic-Polycytidylic Acid in Female Rats: Influence of Sex Hormones and the Participation of Endothelin-1.

Authors:  L C M Coelho; J V Cruz; I K Maba; Aleksander Roberto Zampronio
Journal:  Inflammation       Date:  2020-09-01       Impact factor: 4.092

3.  An integrated strategy by using target tissue metabolomics biomarkers as pharmacodynamic surrogate indices to screen antipyretic components of Qingkaikling injection.

Authors:  Zhixin Zhang; Fang Lu; Haiyu Liu; Huizhen Zhao; Yuehong Liu; Shuang Fu; Meiling Wang; Ziye Xie; Honghong Yu; Zhenghai Huang; Yanling Zhang; Xiaoyan Gao
Journal:  Sci Rep       Date:  2017-07-24       Impact factor: 4.379

4.  Protective role of N-acetyl-l-tryptophan against hepatic ischemia-reperfusion injury via the RIP2/caspase-1/IL-1β signaling pathway.

Authors:  Jianxin Wang; Shuna Yu; Jianguo Li; Huiting Li; Hongxin Jiang; Peilun Xiao; Yitong Pan; Jie Zheng; Li Yu; Jiying Jiang
Journal:  Pharm Biol       Date:  2019-12       Impact factor: 3.503

Review 5.  Central mediators involved in the febrile response: effects of antipyretic drugs.

Authors:  Aleksander R Zampronio; Denis M Soares; Glória E P Souza
Journal:  Temperature (Austin)       Date:  2015-10-13

6.  The Neurokinin-1 Receptor Contributes to the Early Phase of Lipopolysaccharide-Induced Fever via Stimulation of Peripheral Cyclooxygenase-2 Protein Expression in Mice.

Authors:  Eszter Pakai; Valeria Tekus; Csaba Zsiboras; Zoltan Rumbus; Emoke Olah; Patrik Keringer; Nora Khidhir; Robert Matics; Laszlo Deres; Katalin Ordog; Nikolett Szentes; Krisztina Pohoczky; Agnes Kemeny; Peter Hegyi; Erika Pinter; Andras Garami
Journal:  Front Immunol       Date:  2018-02-05       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.